DiaSorin

DiaSorin is an Italian multinational biotechnology and in-vitro diagnostics company headquartered in Saluggia, Piedmont. Its principal business is the development, manufacture and marketing of diagnostic reagent kits and the automated platforms used to process them. The company serves hospital and private laboratories, healthcare professionals and research users across international markets. Its portfolio is concentrated in specialized testing rather than broad routine laboratory diagnostics, with applications spanning infectious diseases, endocrinology, bone and mineral metabolism, hypertension, oncology, onco-hematology, gastrointestinal infections, autoimmunity, and cardiac and neurological markers. The company's origins trace to Sorin Biomedica, founded in 1968 through an initiative associated with Fiat and Montecatini and the Società Ricerche Impianti Nucleari. The in-vitro diagnostics activities later developed under the DiaSorin name. In 1997 Sorin Biomedica was acquired by American Standard, where it became part of a medical systems organization. DiaSorin became an independent Italian group in 2000 following a management buyout led by Carlo Rosa and Gustavo Denegri. The name combines the diagnostic reference in “Dia” with the Sorin heritage. A major turning point came in 2002, when DiaSorin acquired BYC Sangtec and rights connected with the LIAISON platform. This established the foundation for the company's automated specialty immunodiagnostics business. DiaSorin progressively converted earlier enzyme-linked immunosorbent assay products to automated chemiluminescence immunoassay formats and expanded its commercial presence through subsidiaries and distributors. Its LIAISON platform family became the principal vehicle for a broad menu of proprietary assays, while molecular diagnostics added extraction, amplification and detection capabilities for infectious-disease and selected hematological applications. DiaSorin listed its shares on the Italian Stock Exchange in 2007 and later became a constituent of the FTSE MIB index. During the following decade, the company expanded through acquisitions and partnerships. These included the Focus Diagnostics molecular-diagnostics business, the Siemens Healthineers ELISA business, and collaborations with Beckman Coulter, QIAGEN, Meridian Bioscience, TTP and MeMed. The partnerships extended distribution, regulatory access and technology development in areas such as hepatitis, HIV, latent tuberculosis, Helicobacter pylori and host-response testing. The COVID-19 pandemic accelerated DiaSorin's development and regulatory activity. In 2020 it introduced antibody, antigen and molecular tests for SARS-CoV-2, including assays for the LIAISON and Simplexa platforms. Several products received emergency or national regulatory authorizations, including a U.S. Food and Drug Administration authorization for its SARS-CoV-2 serology products. The company also expanded respiratory testing through combined influenza and respiratory syncytial virus assays, and added specimen types and variant-related testing capabilities. In 2021 DiaSorin entered the life-science business more substantially through the acquisition of Luminex Corporation. The transaction added Luminex's xMAP multi-analyte technology, flow-cytometry activities and production sites in the United States and Canada. DiaSorin also introduced the LIAISON IQ point-of-care platform, developed with Lumos Diagnostics, and launched additional SARS-CoV-2 and Lyme-disease solutions in markets accepting the CE Mark. Today, DiaSorin's business model centers on proprietary reagents that operate on dedicated or compatible automated systems. Its manufacturing and development footprint includes facilities in Italy, Germany, the United Kingdom, the United States and Canada. Direct commercial operations cover major markets including the United States, Canada, Mexico, Brazil, China, Australia and Israel, while a network of independent distributors sup…

DiaSorin's historical roots lie in Sorin Biomedica, established in 1968 near the Italian nuclear-research and medical-technology activities associated with Sorin. The company developed diagnostic and medical businesses over subsequent decades. In 1997 American Standard acquired Sorin Biomedica and Immunonuclear Corporation, bringing the businesses into its Medical System Group. The DiaSorin identity emerged as the in-vitro diagnostics activities were reorganized. In 2000 the business became independent through a management buyout led by Carlo Rosa and Gustavo Denegri. The independent group concentrated on diagnostic reagents and laboratory systems, with an emphasis on specialty immunodiagnostics. The 2002 acquisition of BYC Sangtec and rights related to the LIAISON platform was especially important because it gave DiaSorin a scalable automated platform around which it could build a proprietary assay menu. The company also expanded into Mexico, Israel and China and migrated many ELISA products toward automated CLIA formats. DiaSorin's subsequent growth combined internal product development, geographic expansion, acquisitions and commercial alliances. Its immunodiagnostic activities developed across infectious diseases, endocrinology, bone and mineral disorders, oncology, autoimmunity, gastrointestinal infections and cardiovascular or neurological markers. Its molecular-diagnostics business focused particularly on infectious diseases and selected leukemia-related applications, using different sample types including blood, cerebrospinal fluid and swabs. The company entered the Italian public market in 2007. During the mid-2010s it broadened molecular diagnostics through the acquisition of the Focus Diagnostics business unit, added the Siemens Healthineers ELISA business, and formed partnerships with Beckman Coulter and QIAGEN. These relationships supported regulatory submissions and commercial access for hepatitis, HIV and tuberculosis testing. Additional cooperation with Meridian addressed Helicobacter pylori testing, while agreements with TTP and MeMed extended the company's interest into automated point-of-care molecular testing and host-response diagnostics. The COVID-19 period was a major product and regulatory milestone. DiaSorin developed SARS-CoV-2 antibody assays for epidemiological and clinical use, followed by antigen and molecular products. During 2020 and 2021, the company obtained or pursued authorizations in the United States, Canada, Brazil and CE Mark markets. It also expanded respiratory differentiation with a Simplexa assay for influenza A, influenza B and respiratory syncytial virus, and developed assays addressing saliva specimens and SARS-CoV-2 variants. In July 2021 DiaSorin completed its acquisition of Luminex Corporation. This added multi-analyte xMAP technology, flow cytometry and a broader life-science platform to the group's traditional diagnostics operations. In the same period, DiaSorin introduced the LIAISON IQ point-of-care system with Lumos Diagnostics and continued developing infectious-disease products, including Lyme and SARS-CoV-2 tests. The modern group operates manufacturing and commercial facilities across Europe and North America. Its principal technology pillars are automated CLIA and ELISA immunodiagnostics, molecular testing covering extraction, amplification and detection, point-of-care diagnostics, and Luminex multi-analyte and flow-cytometry technologies. DiaSorin remains a publicly traded Italian diagnostics company whose strategy is oriented toward specialized laboratory medicine, proprietary assays and international distribution.

1. 2021Luminex acquisition completed

   The transaction adds xMAP, flow cytometry and life-science capabilities.

   Source
2. 2017Siemens Healthineers ELISA business acquired

   DiaSorin adds the Siemens Healthineers ELISA business to its immunodiagnostics portfolio.

   Source
3. 2016Focus Diagnostics business acquired

   The acquisition expands DiaSorin's molecular-diagnostics activities.

   Source
4. 2007Stock-market debut

   DiaSorin shares begin trading on the Italian Stock Exchange.

   Source
5. 2002BYC Sangtec acquisition strengthens LIAISON

   DiaSorin acquires BYC Sangtec and rights associated with the LIAISON platform.

   Source
6. 2000DiaSorin becomes independent

   A management buyout led by Carlo Rosa and Gustavo Denegri creates an independent DiaSorin group.

   Source
7. 1997Sorin Biomedica joins American Standard

   American Standard acquires Sorin Biomedica and related diagnostics activities.

   Source
8. 1968Sorin Biomedica is founded

   An initiative associated with Fiat and Montecatini establishes Sorin Biomedica, the historical predecessor of DiaSorin.

   Source

A specialist, premium-oriented diagnostics brand focused on automated immunodiagnostics, molecular testing, infectious-disease solutions and laboratory technologies.

• LIAISON XLAutomated immunodiagnostics platform

  A high-throughput automated analyzer supporting DiaSorin's specialty chemiluminescence immunoassay menu. It is designed for clinical laboratories and can operate independently or connect with laboratory automation systems. The platform supports testing in infectious diseases, endocrinology, bone and mineral metabolism, oncology, gastrointestinal disease and other specialty areas.

• LIAISON XSAutomated immunodiagnostics platform2019

  A smaller LIAISON analyzer intended for laboratories with low-to-medium testing volumes. It provides access to selected specialty immunodiagnostic assays in a more compact configuration and has been marketed particularly in European countries.

• LIAISON IQPoint-of-care diagnostics platform2021

  A point-of-care immunodiagnostic platform developed with Lumos Diagnostics. Its initial menu included SARS-CoV-2 antibody testing, followed by an antigen test using nasal and nasopharyngeal samples. The system uses lateral-flow technology in a platform intended to bring specialized testing closer to the point of care.

• Simplexa molecular assaysMolecular diagnostics

  A family of molecular diagnostic tests covering infectious-disease applications. The portfolio includes respiratory assays and SARS-CoV-2 products, and is designed to work with DiaSorin's molecular testing workflow for nucleic-acid extraction, amplification and detection.

• Luminex xMAPLife-science and multiplex testing technology

  A multi-analyte profiling technology obtained through the Luminex acquisition. xMAP enables multiplex analysis of multiple targets in a single sample and broadens DiaSorin's capabilities beyond conventional clinical diagnostic assays into research and life-science applications.

• 2020COVID-19 diagnostic response

  United States · Canada · Brazil · Europe

  DiaSorin rapidly developed SARS-CoV-2 serology, antigen and molecular products during the pandemic, seeking emergency and national authorizations and expanding its respiratory-testing portfolio.

  Outcome. Multiple products received regulatory clearances or emergency authorizations.

  Source

• 2021Acquire Luminex and enter life sciences more deeplyM&A

  DiaSorin sought to broaden its diagnostics platform with multi-analyte and flow-cytometry technologies.

  What changed. The company completed the acquisition of Luminex Corporation in July 2021.

  Aftermath. DiaSorin added xMAP, flow cytometry and additional production facilities in the United States and Canada.

  Source
• 2002Build the automated LIAISON specialty-testing franchiseStrategy

  The acquisition of BYC Sangtec and associated platform rights provided a foundation for automated specialty immunodiagnostics.

  What changed. DiaSorin expanded the LIAISON assay menu and converted selected ELISA products to automated CLIA formats.

  Aftermath. LIAISON became the central platform family for the company's immunodiagnostics business.

  Source

• 2021DiaSorin completes acquisition of Luminex

  The completed transaction expanded DiaSorin into life-science applications and added Luminex's xMAP and flow-cytometry technologies.

  M&A
  Source
• 2021DiaSorin and QIAGEN launch LIAISON LymeDetect

  The partners introduced a Lyme borreliosis testing solution in markets accepting the CE Mark, using technology associated with QIAGEN's QuantiFERON platform.

  Product launch
  Source
• 2020DiaSorin receives FDA authorization for SARS-CoV-2 IgG serology test

  The company obtained U.S. emergency authorization for a serological assay intended to identify antibodies associated with SARS-CoV-2 infection.

  Product launchRegulation
  Source
• 2020DiaSorin expands COVID-19 testing portfolio

  DiaSorin introduced and secured regulatory clearances for SARS-CoV-2 antibody, antigen and molecular tests, including products for the LIAISON and Simplexa platforms.

  Product launchRegulationProduct generation
  Source

1. DiaSorin
2. DiaSorin corporate website